French patient registry for spinal muscular atrophy (SMA 5q)
Part of Brain & nervous system clinical trials.
This trial is a patient registry that collects health information from people with spinal muscular atrophy (SMA) caused by changes in the 5q area. It helps researchers understand real-world care and outcomes for these patients across French hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic test-confirmed diagnosis of SMA type 5q
- You received SMA care (type 1 to 4) at a reference center in France between Sep 1, 2016 and Aug 31, 2024
- You can join by either signing consent (if you’re being followed) or completing an information form and not objecting (if using past data)
- You have health insurance
- You can understand French
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information from people with spinal muscular atrophy (SMA) over time to learn more about the disease and how to improve care. It may help researchers understand SMA better.
This trial is a registry that collects health information from people with spinal muscular atrophy (SMA). It helps researchers understand the condition better and may support future studies and treatments.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.